• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1275703 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type. ~' e/ r9 D0 i2 n% ~
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 & A2 l% D6 d. T% A9 J+ t
+ Author Affiliations, y6 q8 V3 I. i8 M( T

5 r; f) V0 ?! }* a% H6 Z: w1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
2 X5 Z$ X* s8 r7 H  ~2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
- H) D; q- g+ a4 }# p3 H. U1 P9 F) ?3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan " |8 b( K" Y' N0 Z
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
' o9 B: d, T+ x0 E. {1 n0 l- b5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan 2 S0 M% o" A5 F7 {4 g
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan 5 w+ `. {4 H& S$ x9 }9 i, G
7Kinki University School of Medicine, Osaka 589-8511, Japan 5 ^5 S  X6 ]( F$ ~$ a( ^- ~  T
8Izumi Municipal Hospital, Osaka 594-0071, Japan ' N9 L' c7 K8 O1 d* n
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
  e, ^: C8 s/ }6 I9 M* {9 pCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
5 |( n5 {& @3 C% M/ AAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
8 [; I" n3 t" f# M% Y- n( ~9 H8 \$ m  t/ J8 a- o; I
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type 6 l8 F! N. D7 x
' c5 \8 n* m& Q; G, k5 |
Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato # E5 ?) T! s% r# R1 S2 w( V' A' k

  V% ?. ^5 m0 X3 zAffiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  
/ `$ @) c; v  q0 ^& p& x: ?0 e/ Y$ Y6 r, `+ u3 l
Published online on: Thursday, December 1, 2011 ! s5 K) P$ x/ p9 q2 ]8 [! k
( F; {; j- w2 T7 k, j) T
Doi: 10.3892/ol.2011.507 ! y$ ?" X& N/ ?4 X+ C* o
9 G; I6 Y# h6 a- g
Pages: 405-410 * A5 N* q; V8 r

8 Q! H% E! h, JAbstract:' N0 N4 l, s, r
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.
/ b" u+ |5 E2 Y  B # U8 l3 h$ ]& I3 m; P3 N
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
- l- {+ ^2 u* U7 j- ]; c4 vF. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 + ]  a& g9 }: f& i0 {, s8 i
+ Author Affiliations  J6 [# |8 N: k5 ^+ s& `( _) `
1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
9 O1 F* p% t3 h2Department of Thoracic Surgery, Kyoto University, Kyoto
$ s* ^+ v9 _3 ^3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
" l; k6 F$ Q" o  ^&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
' P( o- @$ @5 @6 a( Z- w& fReceived September 3, 2010.
" g3 b! s$ @/ y8 V+ d# tRevision received November 11, 2010.
0 b5 b& G: x* g; W) KAccepted November 17, 2010.
" _% H7 r( }1 pAbstract1 @: y0 g, I1 w- C, N8 v" b- J4 R
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed. " }1 ~1 C- @' a' ~& F, t& l
Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes. 8 r8 q& R3 ^+ J0 c) N
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
. U" v$ c0 K* P8 dConclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study. + ~1 f) [  \. I3 J6 f
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。& Y# q. ~& K- f% |% a2 o/ w
今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?
7 p. U# y- Y. T" D3 T. h
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
( q& n( [+ j3 ^( O$ D# f, J/ \1 Uhttp://clinicaltrials.gov/ct2/show/NCT01523587
7 H+ D- x' A7 I- t
# E8 J( ]3 |  {5 |BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
/ e2 i' w. G/ x6 a6 m4 hhttp://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑
6 ~7 ~  `1 o7 S7 R  A- ~4 I" x8 m- \* _6 G7 Y
从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
# o- ?2 L, Y9 R0 ?: ?% t/ G至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦

1 ^- }: W5 U2 K) }3 B0 m/ q8 I" z没有副作用是第一追求,效果显著是第二追求。- u: e* P9 H# P
不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表